


DAVID Y. IGE
GOVERNOR

LIEUTENANT GOVERNOR'S
OFFICE

'16 SEP 30 08:12



STATE OF HAWAII
DEPARTMENT OF PUBLIC SAFETY
Narcotics Enforcement Division
3375 Koapaka Street, Ste. D100
Honolulu, Hawaii 96819

NOLAN P. ESPINDA
DIRECTOR

CATHY Y. ROSS
DEPUTY DIRECTOR
ADMINISTRATION

JODIE F. MAESAKA-HIRATA
DEPUTY DIRECTOR
CORRECTIONS

SHAWN H. TSUHA
DEPUTY DIRECTOR
LAW ENFORCEMENT

No. Posted at the Office of
the Lieutenant Governor on
September 30,
2016

September 30, 2016

NOTICE OF FEDERAL SCHEDULING ACTIONS

Section 329-11(d) states that if a substance is added, deleted or rescheduled under federal law and notice of the designation is given to the department then the department shall recommend to the legislature that a corresponding change in Hawaii law be made. The Department was given notice that the following depressant drug was placed into Schedule V by the Federal Government:

Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts)..

On May 12, 2016 the Department was given notice that Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts). into schedule V of the Controlled Substances Act (CSA). This scheduling action is pursuant to the CSA which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, or possess) or propose to handle Brivaracetam. The DEA placed an effective date of May 12, 2016 on this scheduling action.

Section 329-22, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows:

§329-22 Schedule V.

“(d) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide], (Vimpat);~~and~~

(2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid][~~;~~]; and

(3) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts)."

This Federal scheduling changes shall take effect on October 31, 2016 as required under Section 329-11(d) HRS.